Arvinas, Inc.
$10.81
▼
-4.24%
2026-04-21 05:24:00
www.arvinas.com
NMS: ARVN
Explore Arvinas, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$703.57 M
Current Price
$10.81
52W High / Low
$14.51 / $5.9
Stock P/E
—
Book Value
$6.83
Dividend Yield
—
ROCE
-20.59%
ROE
-16.23%
Face Value
—
EPS
$-1.14
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
246
Beta
1.98
Debt / Equity
2.05
Current Ratio
4.92
Quick Ratio
4.92
Forward P/E
-3.07
Price / Sales
2.65
Enterprise Value
$15.56 M
EV / EBITDA
-0.14
EV / Revenue
0.06
Rating
Buy
Target Price
$14.88
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 2. | NRx Pharmaceuticals, Inc. | $3.2 | — | $105.82 M | — | 103.85% | 146.18% | $3.84 / $1.62 | $-0.5 |
| 3. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 4. | Context Therapeutics Inc. | $2.26 | — | $223.27 M | — | -65.65% | -46.39% | $3.62 / $0.49 | $0.66 |
| 5. | AIM ImmunoTech Inc. | $0.49 | — | $3.99 M | — | 2638.91% | 251.38% | $19.74 / $0.51 | $-3.19 |
| 6. | Xilio Therapeutics, Inc. | $8.45 | — | $49.46 M | — | -42.66% | -1.33% | $16.52 / $6.47 | $7.79 |
| 7. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 9.5 M | 41.9 M | 22.4 M | 188.8 M | 59.2 M | — |
| Operating Profit | -74.6 M | -43.8 M | -71.5 M | 71.4 M | -58.2 M | — |
| Net Profit | -67.4 M | -35.1 M | -61.2 M | 82.9 M | -45.1 M | — |
| EPS in Rs | -1.05 | -0.55 | -0.96 | 1.3 | -0.71 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 262.6 M | 263.4 M | 78.5 M | 131.4 M |
| Operating Profit | -118.5 M | -250.2 M | -401.5 M | -263.2 M |
| Net Profit | -80.8 M | -198.9 M | -367.3 M | -282.5 M |
| EPS in Rs | -1.26 | -3.11 | -5.74 | -4.42 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 717.9 M | 1.09 B | 1.3 B | 1.27 B |
| Total Liabilities | 284.1 M | 529.8 M | 644.6 M | 703.9 M |
| Equity | 433.8 M | 561.6 M | 660 M | 564.9 M |
| Current Assets | 700.7 M | 1.07 B | 1.28 B | 1.24 B |
| Current Liabilities | 142.5 M | 229.8 M | 257.1 M | 295.1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -273.8 M | -259.3 M | -347.8 M | -273.5 M |
| Investing CF | 407.6 M | 34.7 M | 203.5 M | 242.8 M |
| Financing CF | -91.4 M | 7.9 M | 374.7 M | 4.7 M |
| Free CF | -275.7 M | -261.1 M | -350.7 M | -280.3 M |
| Capex | -1.9 M | -1.8 M | -2.9 M | -6.8 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 235.54% | -40.26% | — | — |
| Earnings Growth % | 45.85% | -30.02% | — | — |
| Profit Margin % | -75.51% | -467.9% | -214.99% | — |
| Operating Margin % | -94.99% | -511.46% | -200.3% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -92.48% | -502.93% | -194.06% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.